|
 The company said its drug, amantadine HCl, significantly reduced
dysfunctional movement, a side effect of levodopa, a drug used to
treat Parkinson's patients.
Patients treated with the drug showed 23 percent reduction in
dysfunctional movement at twelve weeks compared to placebo, company
said.
Emeryville, California-based Adamas said it is also conducting
another late-stage study to evaluate effectiveness of 340 mg dose of
amantadine HCl given once daily at bedtime.
The drug had received orphan drug status from U.S. Food and Drug
Administration in April which gives it several incentives including
seven-year marketing exclusivity.
(Reporting by Vidya L Nathan and Anjali Rao Koppala in Bengaluru;
Editing by Shounak Dasgupta)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
|
